Cancer
Giant Cell Tumor
CI-CAN-00000187Explore in graph →
Non-malignant17 active trials3 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000187Explore in graph →
Clinical trials
52 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04938180 | A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients | terminated | Phase 2 | 4 | AmMax Bio, Inc.INDUSTRY | 3 | May 24, 2024 | clinicaltrials |
| NCT03620149 | Reduced Dose-density of Denosumab for Unresectable GCTB(REDUCE) | terminated | Phase 2 | 2 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Jan 6, 2021 | clinicaltrials |
| NCT00889590 | Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)(HR-GCT) | terminated | Phase 2 | 15 | Leiden University Medical CenterOTHER | 2 | Jan 26, 2016 | clinicaltrials |
| NCT01564121 |
Data updated 22 days agoSource updated May 24, 2024source: clinicaltrials
| Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Zométa(Zometa) |
| terminated |
| Phase 1 / Phase 2 |
| 24 |
| Nantes University HospitalOTHER |
| 1 |
| Aug 30, 2013 |
| clinicaltrials |